277 related articles for article (PubMed ID: 29877637)
1. Quality control of riboflavin-treated platelet concentrates using Mirasol® PRT system: Polish experience.
Lachert E; Kubis J; Antoniewicz-Papis J; Rosiek A; Woźniak J; Piotrowski D; Przybylska Z; Mikołowska A; Marschner S; Łętowska M
Adv Clin Exp Med; 2018 Jun; 27(6):765-772. PubMed ID: 29877637
[TBL] [Abstract][Full Text] [Related]
2. Study of CD69 antigen expression and integrity of leukocyte cellular membrane in stored platelet concentrates following irradiation and treatment with Mirasol® PRT System.
Lachert E; Woźniak J; Antoniewicz-Papis J; Krzywdzińska A; Kubis J; Mikołowska A; Letowska M
Adv Clin Exp Med; 2017; 26(1):7-13. PubMed ID: 28397426
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
[TBL] [Abstract][Full Text] [Related]
4. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?
van der Meer PF; Bontekoe IJ; Daal BB; de Korte D
Transfusion; 2015 Aug; 55(8):1900-8. PubMed ID: 25752624
[TBL] [Abstract][Full Text] [Related]
5. [Effects of use of riboflavin and ultraviolet light for pathogen inactivation on quality of platelet concentrates].
Stanojković Z; Antić A; Stojanović M
Vojnosanit Pregl; 2011 Jun; 68(6):489-94. PubMed ID: 21818915
[TBL] [Abstract][Full Text] [Related]
6. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro.
Zeddies S; De Cuyper IM; van der Meer PF; Daal BB; de Korte D; Gutiérrez L; Thijssen-Timmer DC
Transfusion; 2014 Sep; 54(9):2292-300. PubMed ID: 24689812
[TBL] [Abstract][Full Text] [Related]
7. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.
Picker SM; Steisel A; Gathof BS
Transfusion; 2008 Aug; 48(8):1685-92. PubMed ID: 18513255
[TBL] [Abstract][Full Text] [Related]
8. Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution.
Ignatova AA; Karpova OV; Trakhtman PE; Rumiantsev SA; Panteleev MA
Vox Sang; 2016 Apr; 110(3):244-52. PubMed ID: 26646605
[TBL] [Abstract][Full Text] [Related]
9. Experiences with semi-routine production of riboflavin and UV-B pathogen-inactivated platelet concentrates in three blood centres.
van der Meer PF; Couture C; Hervig T; Kruit G; Devine DV; de Korte D; Kerkhoffs JL
Vox Sang; 2017 Jan; 112(1):9-17. PubMed ID: 28001293
[TBL] [Abstract][Full Text] [Related]
10. Towards the understanding of the UV light, riboflavin and additive solution contributions to the in vitro lesions observed in Mirasol®-treated platelets.
Abonnenc M; Crettaz D; Sonego G; Escolar G; Tissot JD; Prudent M
Transfus Clin Biol; 2019 Nov; 26(4):209-216. PubMed ID: 31563447
[TBL] [Abstract][Full Text] [Related]
11. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.
Picker SM; Oustianskaia L; Schneider V; Gathof BS
Vox Sang; 2009 Jul; 97(1):26-33. PubMed ID: 19302416
[TBL] [Abstract][Full Text] [Related]
12. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage.
Schubert P; Culibrk B; Coupland D; Scammell K; Gyongyossy-Issa M; Devine DV
Transfusion; 2012 Feb; 52(2):397-408. PubMed ID: 21827504
[TBL] [Abstract][Full Text] [Related]
13. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction.
Tauszig ME; Picker SM; Gathof BS
Transfus Apher Sci; 2012 Feb; 46(1):33-7. PubMed ID: 22119364
[TBL] [Abstract][Full Text] [Related]
14. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study.
Picker SM; Steisel A; Gathof BS
Transfus Apher Sci; 2009 Apr; 40(2):79-85. PubMed ID: 19233725
[TBL] [Abstract][Full Text] [Related]
15. The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution.
Reikvam H; Marschner S; Apelseth TO; Goodrich R; Hervig T
Blood Transfus; 2010 Jul; 8(3):186-92. PubMed ID: 20671879
[TBL] [Abstract][Full Text] [Related]
16. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
[TBL] [Abstract][Full Text] [Related]
17. Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets.
Mastroianni MA; Llohn AH; Akkök ÇA; Skogheim R; Ødegaard ER; Nybruket MJ; Flesland A; Mousavi SA
Transfus Apher Sci; 2013 Oct; 49(2):285-90. PubMed ID: 23820429
[TBL] [Abstract][Full Text] [Related]
18. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution.
Picker SM; Tauszig ME; Gathof BS
Transfusion; 2012 Mar; 52(3):510-6. PubMed ID: 21981030
[TBL] [Abstract][Full Text] [Related]
19. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling.
Reid S; Johnson L; Woodland N; Marks DC
Transfusion; 2012 Oct; 52(10):2094-103. PubMed ID: 22320126
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the post-transfusion platelet increment and safety of riboflavin-based pathogen reduction technology (PRT) treated platelet products stored in platelet additive solution for 5 days or less versus 6-7 days.
Kaplan A; Lindgren B; Marschner S; Aznar M; Zalba S; Sánchez P; Ayape ML; Olavarría E; Antelo ML
Transfus Apher Sci; 2016 Apr; 54(2):248-52. PubMed ID: 26345109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]